As well as intracrine kynurenine effects, cancer cells also release kynurenine, which activates the AhR on tumour microenvironment cells, including CD8+ T cells and NK cells, thereby inducing an ‘exhausted’ phenotype, concurrent to increasing PD-1 plasma membrane expression [12]. This evidence concerns the gene PDCD1 and neoplasm.